UY36385A - Piperidinilpirazolopirimidinonas y utilización de las mismas - Google Patents

Piperidinilpirazolopirimidinonas y utilización de las mismas

Info

Publication number
UY36385A
UY36385A UY0001036385A UY36385A UY36385A UY 36385 A UY36385 A UY 36385A UY 0001036385 A UY0001036385 A UY 0001036385A UY 36385 A UY36385 A UY 36385A UY 36385 A UY36385 A UY 36385A
Authority
UY
Uruguay
Prior art keywords
bleeding
prophylaxis
treatment
piperidinilpirazolopirimidinonas
same
Prior art date
Application number
UY0001036385A
Other languages
English (en)
Inventor
Tom Kinzel
Manuel Ellermann
Michael Sperzel
Gaelle Valot
Yolanda Cancho Grande
Jorma Hassfeld
Beyer Kristin
Jan Stampufss
Imke Meyer
Maria Köllnberger
Nils Burkhardt
Joachim Schuhmacher
Matthias Werner
Jörg HEIERMANN
Willem Jan Hengeveld
Susanne Röhrig
Karl-Heinz Schlemmer
Christian Stegmann
Johannes Köbberling
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY36385A publication Critical patent/UY36385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D247/00—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
    • C07D247/02—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00 having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud de patente se refiere a novedosas piperidinilpirazolopirimidinonas sustituidas, a los procesos para la preparación de las mismas, a los compuestos que pueden utilizarse en forma aislada o combinada en un método para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o la profilaxis de sangrado agudo y recurrente en pacientes con o sin trastornos hemostáticos hereditarios o adquiridos subyacentes, donde el sangrado está asociado con una enfermedad o intervención médica a seleccionar a partir del conjunto que consiste en sangrado menstrual abundante, hemorragia post parto, shock hemorrágico, cistitis hemorrágicas, hemorragia gastrointestinal, etc.
UY0001036385A 2014-11-03 2015-11-03 Piperidinilpirazolopirimidinonas y utilización de las mismas UY36385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191410 2014-11-03
EP15165918 2015-04-30

Publications (1)

Publication Number Publication Date
UY36385A true UY36385A (es) 2016-06-01

Family

ID=54365247

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036385A UY36385A (es) 2014-11-03 2015-11-03 Piperidinilpirazolopirimidinonas y utilización de las mismas

Country Status (17)

Country Link
US (1) US10118930B2 (es)
EP (1) EP3215505B1 (es)
JP (1) JP2017533235A (es)
KR (1) KR20170080647A (es)
CN (1) CN107108638A (es)
AU (1) AU2015342021B2 (es)
BR (1) BR112017009207A2 (es)
CA (1) CA2966259A1 (es)
HK (1) HK1243077A1 (es)
IL (1) IL251335A0 (es)
MX (1) MX2017005586A (es)
PE (1) PE20170920A1 (es)
RU (1) RU2713937C2 (es)
SG (1) SG11201703201PA (es)
TW (1) TW201627308A (es)
UY (1) UY36385A (es)
WO (1) WO2016071216A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874209A (zh) * 2017-03-07 2022-08-09 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
US20240124443A1 (en) * 2021-02-05 2024-04-18 Scinnohub Pharmaceutical Co., Ltd Plasmin inhibitor, preparation method therefor, and application thereof
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2527136A1 (en) * 2003-06-03 2004-12-09 Basf Aktiengesellschaft Substituted pyrazolopyrimidines, methods for the production thereof, use of the same for controlling pathogenic fungi, and agents containing said compounds
WO2006023000A1 (en) 2004-07-30 2006-03-02 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
RU2390523C2 (ru) * 2005-10-21 2010-05-27 Мицубиси Танабе Фарма Корпорейшн ПРОИЗВОДНОЕ ПИРАЗОЛ[1,5-a]ПИРИМИДИНА
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EA020825B1 (ru) 2009-04-07 2015-02-27 Эмерити Фарма Аб Аналоги изоксазол-3(2h)-она в качестве терапевтических агентов
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
DK2649075T3 (en) 2010-12-08 2018-07-30 Us Health SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
US9440989B2 (en) * 2012-07-18 2016-09-13 Proyecto De Biomedicina Cima, S.L. Antifibrinolytic compounds
CA2902686C (en) * 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos

Also Published As

Publication number Publication date
RU2713937C2 (ru) 2020-02-11
AU2015342021B2 (en) 2020-02-27
WO2016071216A1 (en) 2016-05-12
EP3215505A1 (en) 2017-09-13
CN107108638A (zh) 2017-08-29
KR20170080647A (ko) 2017-07-10
TW201627308A (zh) 2016-08-01
AU2015342021A1 (en) 2017-05-04
RU2017119419A (ru) 2018-12-05
HK1243077A1 (zh) 2018-07-06
CA2966259A1 (en) 2016-05-12
US20170334917A1 (en) 2017-11-23
SG11201703201PA (en) 2017-05-30
PE20170920A1 (es) 2017-07-12
JP2017533235A (ja) 2017-11-09
BR112017009207A2 (pt) 2019-10-01
IL251335A0 (en) 2017-05-29
EP3215505B1 (en) 2019-07-24
US10118930B2 (en) 2018-11-06
MX2017005586A (es) 2017-06-19
RU2017119419A3 (es) 2019-06-10

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CR20160332A (es) Piridopirazolopirimidonas e indazolopirimidonas como inhibidores de fibrinólisis
UY36385A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
BR112015021888A2 (pt) inibidores de dna-ik
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
BR112017012146A2 (pt) derivado de di-hidroindolizinona
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CO2018006701A2 (es) Formas polimórficas cristalinas del ácido obeticólico
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CO2017002312A2 (es) Compuestos bicíclicos sustituidos
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
UY35602A (es) Compuestos nuevos para el tratamiento del cáncer
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
BR112018073355A2 (pt) gordura e seus usos médicos
MX2020004566A (es) Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.
BR112017012844A2 (pt) piridil-cicloalquil-ácidos carboxílicos substituídos, composições que os contêm e seus usos médicos
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
AR097890A1 (es) Compuestos de urea

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220712